XyloCor Therapeutics is focused on improving the lives of people with cardiovascular disease through our commitment to advancing the science of gene therapy.
Press Release: July 10, 2024
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
More >>
XyloCor’s proprietary products address significant unmet clinical needs in cardiovascular disease.
More >>
XyloCor’s products are enabled by proprietary gene therapy technologies from Weill Cornell Medical College.
More >>